Tivic Health Systems soars after meetings with White House, FDA

Shares of medical device maker Tivic Health Systems TIVC.O rise 232.6% to $11.82 premarket

TIVC says it provided briefings at the White House and FDA which secured positive interest in potential military and defense applications for its biologic and bioelectronic product candidates

Both meetings were held last week in Washington D.C. - TIVC

Separately, co says it discussed the potential for expedited pathways and support for export opportunities for its lead experimental immunotherapy drug called entolimod

Entolimod is being tested in a late-stage study in patients to treat acute radiation syndrome (ARS), a condition caused by exposure to high doses of ionizing radiation

As of last close, TIVC had fallen 40.5% YTD